Benzinga | Nov 5, 2020 07:47AM EST

Intellia Therapeutics Q3 EPS $(0.47) Beats $(0.59) Estimate, Sales $22.22M Beat $15.58M Estimate

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.59) by 20.34 percent. This is a 4.08 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $22.22 million which beat the analyst consensus estimate of $15.58 million by 42.62 percent. This is a 109.31 percent increase over sales of $10.62 million the same period last year.